An interventional study of AID technology and CGM in Type 1 Diabetes, sponsored by University of Aarhus. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by University of Aarhus · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University of Aarhus.
Among the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus, this one has the largest planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2024, is one of 18 with no phase, and was the 19th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →6 of the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 40+
University of Aarhus · Sites in Denmark
Ages 20–70 · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18–65 · Healthy volunteers
University of Aarhus
Ages 15–70
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 20 across the 21 interventional studies, 12 across the 3 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 1 by University of Aarhus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07172672University of AarhusThe TiMeD-T1D Project | 2027-02-01 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Since the introduction of insulin therapy 100 years ago, significant progress has continuously been made in the treatment of people with type 1 diabetes. In the last 10 years, the focus has largely been on technology, and the introduction of automated insulin delivery (AID) systems has revolutionized the treatment of type 1 diabetes. AID is an automated system that works by enabling the insulin pump and continuous glucose monitor (CGM) to communicate with each other, automatically adjusting the subcutaneous insulin dosage according to blood glucose levels. AID technology is predominantly used for individuals with long duration of type 1 diabetes, and due to economic limitations in access to the treatment, it is especially used for those with treatment-related challenges in diabetes regulation. The aim of the Steno Free trials is to investigate whether AID technology combined with on-demand consultations for adults with newly diagnosed type 1 diabetes, compared to conventional standard treatment with a CGM after 1 year of treatment, leads to:
Type 1 diabetes is the result of an autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans in the pancreas, leading to a vital need for insulin treatment. Since the introduction of insulin therapy 100 years ago, significant progress has continuously been made in the treatment of people with type 1 diabetes. In the last 10 years, the focus has largely been on technology, and the introduction of automated insulin delivery (AID) systems has revolutionized the treatment of type 1 diabetes. AID is an automated system that works by enabling the insulin pump and continuous glucose monitor (CGM) to communicate with each other, automatically adjusting the subcutaneous insulin dosage according to blood sugar levels. The technology has been shown to result in significantly better diabetes control, measured by long-term blood sugar levels, hemoglobin A1c (HbA1c), and the time spent in the blood sugar target range (time in range (TIR)) compared to conventional insulin pen treatment. Additionally, the technology generally leads to an improvement in quality of life, manifested through better sleep, reduced anxiety, and fewer worries related to daily life with diabetes. Following these technological advances, a new survey on well-being and satisfaction among people with type 1 diabetes in Denmark has shown that over 85% of adults with diabetes are highly or very highly satisfied with their treatment. Despite this, diabetes distress remains present in 31% of individuals, particularly among young people, both with and without technology. Furthermore, we know that the initial period after a type 1 diabetes diagnosis can be marked by stress and challenges. In clinical practice, AID technology is predominantly used for individuals who have had diabetes for several years, and due to economic limitations in access to the treatment, it is especially used for those with treatment-related challenges in diabetes regulation, despite the fact that the treatment is approved and considered standard care. Through a systematic literature search for international studies, the investigators have not been able to locate studies examining the effect of AID technology for adults with newly diagnosed type 1 diabetes, making this study the first of its kind. With this study, the investigators hope to determine whether early treatment with AID technology can help individuals navigate the initial period after diagnosis more easily and to some extent free them from worries and stress related to diabetes, hence the name Steno Free. The aim of the study is to investigate whether AID technology combined with need-based consultations for adults with newly diagnosed type 1 diabetes, compared to conventional standard treatment with a CGM after 1 year of treatment, leads to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
AID technology combined with on-demand consultations
Device: AID technology
Standard care with insulin pen based therapy combined with CGM
Device: CGM
Automated insulin delivery system combined with a CGM
CGM alone
Less diabetes distress
Less diabetes distress will be measured via the Problem Areas in Diabetes scale (Paid-20) questionnaire.The Problem Areas In Diabetes (PAID) scale is a well- validated, psychometrically robust questionnaire with 20 items.The PAID is a self-report pencil and paper questionnaire that contains 20 items. The higher score the more negative emotions related to diabetes.
Time frame: Paid-20 score will be assessed at baseline (inclusion), 3 months after inclusion and annually until end of study (anticipated average 24 months, but till the year 2028)
Increased quality of life
Increased quality of life will be measured via the Well-being index (WHO-5) questionnaire. The higher score the more quality of life. (The WHO-5 is focused on subjective quality of life based on positive mood (good spirits, relaxation), vitality (being active and waking up fresh and rested), and general interest (being interested in things). A score below 50 can indicate poor well-being which may be secondary to a depressive disorder or other etiology and is an indication for further evaluation.
Time frame: Paid-20 score will be assessed at baseline (inclusion), 3 months after inclusion and annually until end of study(anticipated average 24 months, but till the year 2028)
Increased health literacy
Increased health literacy will be measured via the Health Literacy questionnaire (HLQ).The HLQ has nine scales that each measure an aspect of the multidimensional construct of health literacy. All scales have good psychometric properties. The higher score the more health literacy.
Time frame: Paid-20 score will be assessed at baseline (inclusion), 3 months after inclusion and every 12 months until end of study(anticipated average 24 months, but till the year 2028)
Glucose regulation 1
CGM data including Time In Range (TIR) for the last 14 days measured by a dexcom sensor
Time frame: TIR will be measured at baseline (inclusion) and every 12 months until end of study (anticipated average 24 months, but till the year 2028)
Glucose regulation 2
CGM data including Time above range (TAR) for the last 14 days measured by a dexcom sensor
Time frame: TAR will be measured at baseline (inclusion) and every 12 months until end of study (anticipated average 24 months, but till the year 2028)
Glucose regulation 3
CGM data including Time below range (TBR) for the last 14 days measured by a dexcom sensor
Time frame: TBR will be measured at baseline (inclusion) and every 12 months until end of study (anticipated average 24 months, but till the year 2028)
Glucose regulation 4
CGM data including estimated haemoglobin A1C via a dexcom sensor
Time frame: Estimated A1c will be measured at baseline (inclusion) and every 12 months until end of study(anticipated average 24 months, but till the year 2028)
Insulin dosage
insulin dosage from both groups
Time frame: insulin dosage will be measured at baseline (inclusion) and every 12 months untill end of study(anticipated average 24 months, but till the year 2028)
Number of hospitalizations
number of hospitalizations due to hypoglycemia or diabetic ketoacidosis
Time frame: Will be measured retrospectively from start of study October 2024 until the end of the study(anticipated average 24 months, but till the year 2028)
Consultations with the health care professionals
amount of physical or virtual consultations
Time frame: Data will be retrospectively collected at the end of the study (anticipated average 24 months, but till the year 2028)
Sick days
participants will be asked at the regularly visit at the hospital the amount of sick days since last consultation
Time frame: Data will be retrospectively collected at the end of the study(anticipated average 24 months, but till the year 2028)
Qualitative interviews
Qualitative interviews with emphasis on their own experience participating in the study
Time frame: 3 months and 12 months after inclusion (anticipated average 24 months, but till the year 2028)
No study locations are listed for this record.
Plan to share: Yes — data will be shared upon reasonable request
Supporting information: Study protocol
Time frame: after study end (October 2028)
Access criteria: Upon request to the first author they will be given acces to individual data captured at baseline and during the study period
Data sharing details ↗ · easyupload.io
No publications or documents are linked to this record.
Start is estimated for Oct 2024; primary completion for Oct 2028, 48 months later.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 48 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.